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Abstract: Electrophilic (het)arenes can undergo reactions with nucleophiles yielding pi- or
Meisenheimer (σ-) complexes or the products of the SNAr addition/elimination reactions. Such
building blocks have only rarely been employed for the design of enzyme inhibitors. Herein, we
demonstrate the combination of a peptidic recognition sequence with such electrophilic (het)arenes
to generate highly active inhibitors of disease-relevant proteases. We further elucidate an unexpected
mode of action for the trypanosomal protease rhodesain using NMR spectroscopy and mass
spectrometry, enzyme kinetics and various types of simulations. After hydrolysis of an ester
function in the recognition sequence of a weakly active prodrug inhibitor, the liberated carboxylic
acid represents a highly potent inhibitor of rhodesain (Ki = 4.0 nM). The simulations indicate
that, after the cleavage of the ester, the carboxylic acid leaves the active site and re-binds to the
enzyme in an orientation that allows the formation of a very stable pi-complex between the catalytic
dyad (Cys-25/His-162) of rhodesain and the electrophilic aromatic moiety. The reversible inhibition
mode results because the SNAr reaction, which is found in an alkaline solvent containing a low
molecular weight thiol, is hindered within the enzyme due to the presence of the positively charged
imidazolium ring of His-162. Comparisons between measured and calculated NMR shifts support
this interpretation.
Keywords: cysteine protease; rhodesain; electrophilic (het)arene; nucleophilic aromatic substitution;
Meisenheimer complex; pi-complex; prodrug
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1. Introduction
Inhibition of enzymes may occur either reversibly or irreversibly. In the case of irreversible
inhibition, a covalent reaction between a nucleophilic amino acid (in most cases, an activated Cys,
Ser or Thr side chain), either of the active or an allosteric site, reacts with an electrophilic functional
group of the inhibitor, the so-called “warhead”. Besides this reactive building block, enzyme inhibitors
also contain a recognition unit fitting into the substrate binding pockets. In the case of protease
inhibitors these are mainly peptidic or peptidomimetic sequences. However, not all covalent reactions
of enzyme and inhibitor lead to irreversible inhibition, and this has received increasing attention
in drug development in the last years to design covalent, but reversible inhibitors due to several
advantages over non-covalent inhibitors such as longer target residence times or higher potency and
ligand efficiency (for reviews on this topic see [1–8]).
In contrast to classical electrophilic building blocks like Michael-acceptor systems [9–17],
nitriles [18–21], aldehydes, ketones [22–24], three-membered heterocycles [25–28] or a iodoacetic acid
moiety [29,30], (hetero)aromatic electrophiles, which can react via nucleophilic addition (yielding pi- or
σ-complexes) or substitution reactions (SNAr) have only rarely been employed [31–35]. Such aromatic
moieties have also seldom been investigated as non-covalently binding parts of the recognition units
of enzyme inhibitors [36,37].
We therefore aimed to explore the potential of such groups as new building blocks for cysteine
proteases of the papain family, specifically the human cathepsins B and L, and the Trypanosoma
protease rhodesain. The human enzymes of this family play crucial roles in tumor diseases [38,39].
The cathepsin L-like protease rhodesain from Trypanosoma brucei rhodesiense, the parasite causing
human African trypanosomiasis (HAT), is essential for the parasite’s survival, since it is involved in
several pathological processes in the host. These include, e.g., the crossing of the parasite through the
blood–brain barrier as well as the turnover of variant surface glycoproteins (VSGs), and degradation of
host immunoglobulins [40,41].
In the current proof-of-principle study, we tested the overall potency of (hetero)aromatics
as building blocks for peptidic protease inhibitors. Since we were interested in the inhibition
properties of the (hetero)aromatic moiety, we used the same recognition unit, the dipeptide
sequence H2N-l-Phe-l-Leu-OBn, and attached various (hetero)aromatic electrophiles to its N-terminus.
This dipeptide was chosen for two reasons: (1) It was previously shown to be an appropriate recognition
unit for cathepsin L-like cysteine proteases supposed to bind into the substrate-binding pockets in an
anti-substrate orientation [14,15,42]; (2) In contrast to amino acids with functionalized side chains, no
additional protection/deprotection steps are necessary during synthesis.
For one inhibitor, we observed that the benzyl ester of the recognition unit was hydrolyzed by the
target proteases. Intriguingly, the resulting free acid (with HN-l-Phe-l-Leu-OH moiety) represents a
nanomolar inhibitor against rhodesain.
The inhibition potencies of the new inhibitors were tested on the human cathepsins B and L (cath.
B, cath. L), the cathepsin L-like protease rhodesain (rhod.) from T. b. rhodesiense, and, in order to
check their selectivity and to exclude promiscuous inhibition, on the Staphylococcus aureus cysteine
protease and transpeptidase sortase A with a “reversely protonated” catalytic cysteine residue [43], as
well as on the serine protease of the Dengue virus (DENV PR), which shares the P1 specificity for Arg
with cathepsins.
The formation of a complex between inhibitor and the target protease rhodesain was indicated
by mass spectrometry and NMR spectroscopy. Possible binding modes of selected inhibitors were
analyzed by docking, followed by subsequent molecular dynamics (MD) simulations. Additionally,
we performed quantum mechanical (QM) computations for model systems and quantum mechanics /
molecular mechanics (QM/MM) simulations, which include the enzyme environment.
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2. Results
2.1. Syntheses
The synthesis of the new inhibitors started from commercially available l-leucine benzyl ester
p-toluenesulfonate and Boc-protected l-phenylalanine, which were coupled by carbodiimide chemistry.
The dipeptide product was easily purified by recrystallization (Scheme 1). Deprotection with either
hydrochloric acid in dioxane (4 M) or trifluoro-acetic acid (TFA) in dichloromethane (DCM)(40%)
afforded the ammonium salt, which was directly used in the subsequent steps.
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The potential inhibitors were synthesized either by SNAr reaction on a (hetero)aromatic unit
carrying two potential leaving groups (compounds 2, 3, and 7) or by reaction with an electrophilic
group attached to the ring system (e.g., acid chloride, isocyanate and compounds 1, 4, 5, and 6,
Scheme 2).
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To further investigate whether the hydrolysis product of compound 7 is the active compound as
indicated by MS, NMR and hydrolysis studies (see Sections 2.3–2.5), the corresponding free acid 8 was
also synthesized (Scheme 3). First attempts to cleave the benzyl ester of compound 7 with PPL (porcine
pancreatic lipase) were unsuccessful. The compound was synthesized starting from the fully protected
dipeptide Boc-NH-l-Phe-l-Leu-OBn. In a first step, the benzyl ester was removed by hydrogenolysis.
A short filtration over celite yielded a crude material that was subjected to acidolytic removal of the
Boc-protecting group with trifluoroacetic acid (TFA). The solvent was removed to perform the reaction
with the warhead (1,2-difluoro-4,5-dinitrobenzene) in ethanol in the presence of triethylamine. After 21
h at 80 ◦C, the desired acid 8 was obtained after purification by preparative high-performance liquid
chromatography (HPLC).
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2.2. Enzyme Assays
Inhibition of cathepsins and rhodesain was tested with the fluorogenic substrate
Cbz-Phe-Arg-AMC as described previously [19]. First, a screening at 20 µM inhibitor concentration
was performed. For compounds showing >60% inhibition at this concentration, the IC50 values were
determined. For the most active compounds, namely 4 and 7, the IC50 values were determined at
different substrate concentrations in order to check for competitive or non-competitive inhibition [44,45].
IC50 values were found to increase linearly with increasing substrate concentrations in both cases,
indicating competitive inhibition (see exemplarily Figure 1 for compound 7). The respective Ki values
(Table 1) were determined from plots of the IC50 values against substrate concentration according to
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Table 1. Inhibition data for inhibitors of the general structure R-NH-l-Phe-l-Leu-OBn, % inhibition at
20 µM and Ki [µM] 1.
Cpd. Cath. L Cath. B Rhod. DENV PR Sortase A
% inh./Ki % inh./Ki % inh./Ki % inh./Ki % inh./Ki
1 57/nd 16/nd nd/nd 19/nd nd/nd
2 56/nd 33/nd nd/nd 24/nd nd/nd
3 60/nd 22/nd nd/nd 28/nd nd/nd
4 99/0.66 20/nd 75/0.29 10/nd 11/nd
5 8/nd 10/nd nd/nd 11/nd nd/nd
6 50/nd 21/nd nd/nd 12/nd nd/nd
7 98/1.6 63/4.4 45/nd 31/nd 16/nd
1 All values are from at least three independent measurements; standard deviations are 10% or less; nd, not
determined; cpd., compound; Cath. L, cathepsin L; Cath. B, cathepsin B; Rhod.; rhodesain, DENV PR, Dengue
virus protease.
The progress curves for inhibition of cathepsins and rhodesain by the compounds were found to be
linear in all cases, i.e., no time-dependent inhibition was observed, pointing to fast reversible inhibition.
The highest inhibition of cathepsin L was found with the benzoic acid amide 4 (Ki = 0.66 µM) and
the amine 7 (Ki = 1.6 µM). The latter also turned out to be the best inhibitor of cathepsin B and the
Dengue virus (DENV) protease [47,48], however with lower inhibitory potency (Cath. B: Ki = 4.4 µM;
DENV PR: 31% at 20 µM). These two compounds were also tested for inhibition of the cathepsin L-like
parasitic protease rhodesain. While only a weak inhibitory potency (45% inhibition at 20 µM) was
detected for compound 7, the amide 4 displayed a Ki value of 0.29 µM.
The benzyl ester 7 was found to be hydrolyzed, yielding the free acid 8 (see Sections 2.3–2.5).
Thus, the enzyme assays were also performed with the acid 8. Ki values of 3.0 ± 0.9 µM for cathepsin
L (n = 10), 1.50 ± 0.29 µM for cathepsin B (n = 6) and, most interestingly, 4.0 ± 1.3 nM (n = 14) for
rhodesain, were determined (Figure 2). This indicates that acid 8 and ester 7 are similarly active on
cathepsins L and B, whereas in the case of rhodesain, an enormous increase in inhibition potency was
observed comparing the benzyl ester 7 and the respective free acid 8.
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To investigate the inhibitory effects against a cysteine protease with a protonated thiol instead of
an imidazolium/thiolate dyad, compounds 4, 7 and 8 were tested for inhibition of the S. aureus sortase
A. None of the inhibitors showed significant inhibition at a final inhibitor concentration of 20 µM
(compound 4: 11%; compound 7: 16%; compound 8: 0%), indicating selectivity for cysteine proteases
from the CA-clan (cathepsins and rhodesain) over the CL-clan sortase A [49].
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The progress curves for inhibition of cathepsins L and B and rhodesain by compound 8 did not
clearly show time-dependent behavior. Since the inhibition mechanism (reversible vs. irreversible)
can unequivocally not be deduced from the progress curves, we also used other methods to ascertain
the (ir)reversibility of the inhibition: (A) The IC50 values for inhibition of rhodesain were determined
in dependence of incubation time of enzyme and inhibitor prior to substrate addition (10 min vs.
45 min). No differences were observed indicating reversible inhibition; (B) Furthermore, dilution assays
were performed with rhodesain. To this end, the enzyme was completely inhibited by an inhibitor
concentration 100 fold higher than the IC50 value. After dilution of the enzyme-inhibitor mixture with
a buffer by a factor of 100, slow and time-dependent reactivation of the enzyme was observed, finally
proving the reversibility of inhibition (see Supplementary Material).
2.3. 19F NMR Spectroscopy
The interaction of the fluorinated inhibitors 7 and 8 with rhodesain was probed via 19F NMR
spectroscopy (Figure 3). Compound 7 displayed some solubility issues apparent from the observed
turbidity of the sample and the reduced signal-to-noise ratio in the spectrum (Figure 3a). To probe the
rhodesain-mediated turnover of 7 into 8, we recorded time-resolved 19F NMR spectra of 7 (800 µM) in
the presence of 4 µM rhodesain (Figure 3b). During the measurement, the solution became clear and a
dramatic difference in the chemical shift occurred to values identical to those observed for compound
8. The reaction was subsequently analyzed by MS (see Section 2.4), which confirmed the formation of
the free acid 8.
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Figure 3. 19F NMR spectra: (a) Ester 7 and acid 8 are readily distinguishable by their chemical shifts.
(b) Time-resolved 19F NMR shows rhodesain-dependent turnover of 7 into 8. As a control, a separate
spectrum of the expected amount of compound 8 that should have formed from 7 in the NMR-based
enzymatic assay is recorded (blue trace). Due to the poor solubility of compound 7 (compare (a)), no
peak was observed within the 128 scans run for each time-trace. Upon addition of rhodesain, the turbid
sample gradually turned clear and the resonance for compound 8 appeared. Therefore, the spectral
region has been confined to that displaying the chemical shift for compound 8. (c) Acid 8 forms a stable
complex (asterisk) with rhodesain. The peak intensity depends on the amount of protein. For reference,
the spectrum of free compound 8 (blue) is included (as shown in (a)).
To observe the chemical shift of the rhodesain-bound reaction product, a higher concentration of
rhodesain (150 or 450 µM) was incubated with 8. Indeed, a new, broad peak (Figure 3c, asterisk) was
observed, which prob bly results from an enzyme-inhibitor a duct (see Sections 2.6 d 2.7).
2.4. Mass Spectrometry
To further characterize the interaction between rhodesain and the different inhibitors, we
performed a liquid chromatography-mass spectrometric (LC–MS coupled to nano-ESI-Q-TOF) analysis
of rhodesain that had been incubated with compounds 4 or 7. Samples were analyzed in positive ion
mode on a quadrupole time-of-flight mass spectrometer (Synapt G2-S HDMS, Waters Corporation)
using electrospray ionization (ESI). Rhodesain without inhibitor served as a control. Both compounds
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reacted with rhodesain (Figure 4). Interestingly, we found that rhodesain catalyzes the hydrolysis of
the benzyl esters of the dipeptide recognition units to the corresponding acids, indicated by a mass
shift of 90 Da corresponding to the loss of the terminal benzyl group (Figure 4). Notably, only reaction
products of the hydrolyzed compounds with rhodesain were detectable by LC–MS analysis. Since
the NMR experiments also showed conversion of ester 7 into the acid 8 catalyzed by rhodesain, the
LC–MS analyses were repeated with the acid 8. These experiments revealed the formation of an adduct
with rhodesain for both acid 8 and ester 7 showing exactly the same pattern (Figure 4). These data
are in line with the previous NMR spectroscopic observation that the benzyl ester of the dipeptide
recognition unit is first hydrolyzed by rhodesain, which subsequently forms a very stable complex
with the hydrolysis product. This may also hold true for inhibitor 4. Since the complex formation is
reversible—as shown by the enzyme assays discussed above—and the mass spectra show the mass of
the adduct of enzyme and acid 8 and not the mass of an adduct resulting from nucleophilic substitution
of either the fluoride or a nitro group, the SNAr reaction cannot be completed. Hence, the data are only
consistent with a pi- or a Meisenheimer (σ-) complex.
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2.5. Hydrolysis of Ester 7 by Rhodesain
In order to verify that the ester cleavage of compound 7 indeed occurs by enzymatic hydrolysis
catalyzed by the target protease rhodesain, the compound was incubated with: (a) catalytically active
rhodesain; (b) reaction buffer; or (c) rhodesain inactivated by the vinyl sulfone K11777 [50]. The reaction
mixtures were subsequently analyzed by LC–MS. Unconverted ester 7 and acid 8 were eluted at t(8) =
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0.9 min and t(7) = 2.1 min. The detected masses matched the theoretical values ([7 + H+] = 553.3 m/z,
[7 + Na+] = 575.4 m/z, [8 + H+] = 463.3 m/z and [8 + Na+] = 485.3 m/z). A complete conversion of the
ester 7 into acid 8 was observed in the case of catalytically active rhodesain (a) (Figure 5), but not with
the irreversibly inactivated enzyme (c). A control showed that the ester was not hydrolyzed by the
reaction buffer (b) (Figure 5).
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2.6. Reaction of Inhibitor 7 with a Low Molecular eight Thiol
Since cathe sins and rhodesain are cysteine proteases, we also investigated the interaction between
the inhibitor 7 and a low molecular weight thiol (LMW thiol). The reaction of compound 7 was carried
out with 2-phenylethanethiol (9) in t e presence of a base in ethanol (Sc eme 4). All three possible
reaction products resulting from substitution of the nitro- (10), fluoro- (11) and of both groups (12)
were obtained in the experiments, in which the reaction temperature (rt or 80 ◦C), the amounts of thiol
and base (excess or two equivalents each) and the reaction time (4 h, 16 h, 28 h) were varied. The main
product (ca. 60–70%) etected in the 16 h reaction at 80 ◦C with a large excess of thiol and triethylamine
was the double-substitution pro uct (12) accompanied by small amounts of 10 and 11. At rt with two
eq. base and thiol, ca. 70–80% unreacted starting material, accompanied by small amounts of all three
reaction products (10–12), was detected. After 28 h at rt (2 eq. base and thiol), the amount of starting
material decreased (to ca. 40%) and the amounts f the three substitution pr ducts (10–12) increased
(t ca. 15–25% each). These reactions show t at t e chosen electrophilic aromatic moiety is indeed
c petent to undergo nucleophilic ar matic substituti ns.
The regiochemistry of the substitution in product 12 could not be unequivocally determined by
the usual 2D NMR methods, so that DFT calculations and a DP4-probability analysis were performed.
The observed NMR chemical shifts were compared with those of values for both possible regioisomers
computed by DFT calculations. Conformational analyses were performed on a PM6 (Parametric
Method 6) [51] or MMFF (Merck Molecular Force Field) [52] level of theory and the geometries of all
conformers found were subsequently reoptimized [B3LYP/6-31G(d)] [53–59]. For the calculation of
the NMR shielding tensors, the mPW1PW91 [60] functional was used in combination with the 6-31
+ G(d,p) [57–59] basis set and the gauge-independent atomic orbital (GIAO) method [61]. For this
computation, undirected solvent effects were taken into account using the integral equation formalism
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polarizable continuum model (IEFPCM) [62]. After Boltzmann weighting, the DP4+ probabilities [63]
(see Supplementary Material) were calculated, which unambiguously show that the most likely
regioisomer is the one with both thioether moieties in para-position to each other (12).Molecules 2020, 25, x FOR PEER REVIEW 9 of 23 
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Structure ωB97XD MP2 SCS-MP2 
High level quantum chemical calculations for appropriate model systems are often very helpful
to understand the situation in an enzyme [28,64–66]. Hence, to shed some light on possible reaction
intermediates, we also co puted the relative stabilities of the involved Meisenheimer complexes
in a polar solvent. To mimic the polar environment, we used the IEFPCM approach for a water
environment [62]. To obtain information about the influence of the employed theoretical approach, we
used density functional (ωB97XD [67]/6-31 + G* [59]) as well as the more reliable 2nd order perturbation
theory without and with the SCS (spin-component-scaled) [68] approximation. For these computations
we also employed t e 6-31 + G* basis set. All computations were performed with the GAUSSIAN
program package [69]. The data are summarized in Table 2. The computed structures are depicted in
Figure 6. In all model systems, the inhibitor was approxi ated by the substituted benzene ring.
Table 2. Stabilities (only thiolate/thiolate and imidazolium: full optimization/thiolate and imidazolium:
R(S-CX) fixed at 1.9 Å) of the Meisenheimer complexes in a polar solvent [in kcal/mol]. For all
calculations the 6-31 + G* basis sets were employed. For further information see main text and Figure 6.
Structure ωB97XD MP2 SCS-MP2
Pre-complex –8.8/–9.0/ –12.3/–16.0/- –10.3/–12.8/
S-CH +0.8/–11.5/–6.8 –6.6/–16.0/–12.8 –4.1/–12.9/–9.3
S-CF –3.3/–13.1/–3.1 –13.2/–20.3/–12.5 –11.1/–16.5/–10.1
S-NO2 –2.7/–9.3/+3.3 –11.9/–17.0/–5.3 –9.1/–13.3/–2.9
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Figure 6. Computed structures and 19F shifts relative to the 19F shift of the free inhibitor for the different
model systems. For the undistorted inhibitor the following distances are obtained: R(CAr. . . F) = 1.35 Å,
R(CAr. . . NO2) = 1.47 Å and R(CAr. . . H) = 1.085 Å. For further explanation see main text; 1 with respect
to the NO2 group in meta-position to F; 2 with respect to the NO2 group in para-position to F. MP2,
second-order Møller–Plesset perturbation theory.
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The model system without an imidazole ring mimics the situation of the reaction with
2-phenylethanethiol (9) in the presence of a base in ethanol, in which the reaction can be viewed as a
simple thiolate attack at the substituted ring. The corresponding complexes are depicted in Figure 6 in
the row “only thiolate”. They were obtained by a full geometry optimization starting with a S. . . CX
distance (X = F, NO2, H) of 1.9 Å. The resulting complexes represent Meisenheimer complexes as can be
deduced from the distances: the distances R(S. . . CX) remain at about 1.9 Å and the distances R(CAr. . . X)
are already considerably elongated. According to the more accurate MP2 or SCS-MP2 computations,
the Meisenheimer complexes represent stable minima on the hypersurface, which lie about 4–13
kcal/mol lower than the reactants. The computations also indicate a stable pre-complex stabilized
by a hydrogen bond between the NH group and the attacking thiolate, which according to the more
accurate MP2- and SCS-MP2-calculations, is similarly stable as the Meisenheimer complexes. It should
be noted that wB97XD considerably underestimates the stability of the Meisenheimer complexes.
The computations are in good agreement with the experiment, which finds SNAr reactions between
2-phenylethanethiol (9) in the presence of a base in ethanol at rt. Figure 6 also contains the 19F NMR
shifts relative to the value computed for the inhibitor. The computed variation upon the formation
of the Meisenheimer complexes are magnitudes larger than the variation found experimentally for a
possible inhibitor-enzyme complex (≈ 1 ppm).
Possible reactions between the substituted aromatic ring and the catalytic dyad of the enzyme differ
from the solvent reaction in several ways. Besides steric restrictions, the thiolate group of the active-site
cysteine residue is always stabilized by a strong salt bridge to the positively charged imidazolium
ring of the active-site histidine residue, which might reduce the thiolate reactivity. To mimic this
situation, we added a positively charged imidazolium ring to the model system. In the first calculation,
we put the thiolate at a distance of about 1.9 Å from the attacked carbon center of the aromatic ring
and performed a full geometry optimization. The resulting complexes are depicted in Figure 6 as
“thiolate and imidazolium: full optimization”. The more reliable MP2- or SCS-MP2-computations
predict that the resulting complexes are stable with respect to the fragmentation into the inhibitor and
thiolate/imidazolium complex. The computed complexes, however, are not Meisenheimer complexes
as found for the situation without the imidazolium (only thiolate). The R(S. . . CX) distances are about
3.9–4.0 Å and the R(CAr. . . X) are not elongated. Nevertheless, the stability of this complex upon
fragmentation into inhibitor and thiolate/imidazolium complex is about 20 kcal/mol, i.e., they are even
more stable than the Meisenheimer complexes found for the “only thiolate” situation. It should be
noted that the situation found for the attack at C−NO2 does not reflect the situation in the enzyme,
because the thiolate and the imidazolium ring interchange their positions during the full optimization
to maximize the interaction energy. The same holds true for the attack at C−F due to the orientation of
the substituted ring. Both the pre-complex and the situation found for the attack at the CH group of the
ring could also take place in the enzyme (see Section 2.7). To get more insights, we also built a complex
in which we fixed the S–CX bond lengths to about 1.9 Å, i.e., we enforced a kind of Meisenheimer
complex in which the positively charged imidazolium is present. According to MP2 or SCS-MP2, the
resulting complexes (Figure 6: thiolate and imidazolium: R(S−CX fixed at 1.9 Å)) are 4–10 kcal/mol less
stable than the complex obtained by the full optimization. This indicates that a thiolate/imidazolium
complex should not be able to form a Meisenheimer complex. Again, the 19F NMR shifts were
computed. Their variations with respect to the 19F NMR shift of the pure inhibitor are also given in
Figure 6. It can be seen that the NMR shift variations found for the complexes are considerably smaller
than those found for the corresponding Meisenheimer complexes. Furthermore, they are of similar size
as the experimental shift difference. The comparison between the employed theoretical approaches
clearly shows that the DFT functionalωB97XD underestimates the stability of the complexes by up to
10 kcal/mol.
Our model calculations indicate that the catalytic dyad of the enzyme, mimicked by a
thiolate/imidazolium complex, behaves differently than a single attacking thiolate. Consequently,
the formation of a Meisenheimer complex would not be expected for the enzyme, but instead, the
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formation of a quite stable complex with larger distances between the catalytic dyad and the substituted
aromatic ring would be expected. From the orientation of the fragments, it resembles a pi-complex.
Despite this relatively long distance, the complex is quite stable. The magnitudes of the computed
NMR shifts also indicate that a pi- instead of a Meisenheimer complex is formed.
2.7. Theoretical Investigations of the Enzyme-Inhibitor Complex
Docking studies using the crystal structure of rhodesain (pdb 2p7u) were performed with acid 8
and its benzyl ester 7 to understand the molecular basis of the observed enzyme inhibition by acid 8
and of the observed enzymatic hydrolysis of ester 7 in more detail. Docking was performed with the
FlexX/LeadIT 2.3.2 software suite [70]. The detailed procedure is given in the Supplementary Material.
For the benzyl ester 7, three different kinds of poses were found. In the highest ranked pose
(i.e., the pose with the most negative score of –20.56), the electrophilic aromatic ring binds to the S1′
pocket and is not close to the cysteine (see Figure S3 in the Supplementary Material for more details).
In various other highly stable poses, this inhibitor moiety sits in the active site and hence is close to
the active site cysteine (score –18.26, see Figure S4 in the Supplementary Material for more details).
Additionally, multiple poses with a substrate-like orientation of compound 7 were predicted with the
benzyl ester being in a position close to the cysteine (distance 3.2 Å, score –13.77, Figure 7). In this
orientation, the ester carbonyl carbon atom is in a suitable position for nucleophilic attack initiating the
hydrolysis of the ester.
Molecules 2020, 25, x FOR PEER REVIEW 12 of 23 
 
Our model calculations indicate that the catalytic dyad of the enzyme, mimicked by a 
thiolate/imidazolium complex, behaves differently than a single attacking thiolate. Consequently, the 
formation of a Meisenheimer complex would not be expected for the enzyme, but instead, the 
formation of a quite stable complex with larger distances between the catalytic dyad and the 
substituted aromatic ring would be expected. From the orientation of the fragments, it resembles a 
π-complex. Despite this relatively long distance, the complex is quite stable. The magnitudes of the 
computed NMR shifts also indicate that a π- instead of a Meisenheimer complex is formed. 
2.7. Theoretical Investigations of the Enzyme-Inhibitor Complex 
Docking studies using the crystal structure of rhodesain (pdb 2p7u) ere performed with acid 
8 and its benzyl ester 7 to understand the molecular basis of the observed enzyme inhibition by acid 
8 and of the observed enzymatic hydrolysis of ester 7 in more detail. Docking was performed with 
the FlexX/LeadIT 2.3.2 software suite [70]. The detailed procedure is given in the Supplementary 
Material.  
For the benzyl ester 7, three different kinds of poses were found. In the highest ranked pose (i.e., 
the pose with the most negative score of –20.56), the electrophilic aromatic ring binds to the S1′ pocket 
and is not close to the cysteine (see Figure SI 3 in the Supplementary Material for more details). In 
various other highly stable poses, this inhibitor moiety sits in the active site and hence is close to the 
active site cysteine (score –18.26, see Figure SI 4 in the Supplementary Material for more details). 
Additionally, multiple poses with a substrate-like orientation of compound 7 were predicted with 
the benzyl ester being in a position close to the cysteine (distance 3.2 Å, score –13.77, Figure 7). In this 
orientation, the ester carbonyl carbon atom is in a suitable position for nucleophilic attack initiating 
the hydrolysis of the ester.  
Figure 7. Substrate-like binding mode of ester 7. Light grey: solvent accessible surface of rhodesain; 
magenta: carbon atoms of rhodesain amino acid residues; orange: carbon atoms of ester 7; blue: 
nitrogen; red: oxygen; yellow: sulfur; cyan: fluorine. 
In this reverse, i.e., substrate-like orientation, the carbonyl oxygen of the ester group points 
towards Gln-19. The benzyl group extends into the S1′ pocket and the leucine residue is located in 
the S1 pocket. The phenylalanine side chain occupies the S2 pocket, and the aromatic ring is placed 
in the S3 pocket. 
To investigate the stability of the poses in more detail, three MD simulations for each pose were 
performed. The poses in which the electrophilic aromatic ring sits in the active site were found to be 
S3
S2
S1
S1‘
ASP-161
GLN-19
CYS-25
GLY-66
Figure 7. Substrate-like binding mode of ester 7. Light grey: solvent accessible surface of rhodesain;
magenta: carbon atoms of rhodesain amino acid residues; orange: carbon atoms of ester 7; blue:
nitrogen; red: oxygen; yellow: sulfur; cyan: fluorine.
In this reverse, i.e., substrate-like orientation, the carbonyl oxygen of the ester group points
towards l - . extends into the S1′ pocket and the leucine residue is located in the
S1 pocket. The phenylalanine side chain occupies the S2 pocket, and the arom tic ring is placed in the
S3 pocket.
To investigate the stability of the poses in ore detail, three D simulations for each pose were
performed. The po es in w ic the electrophilic aromatic ring sits in the active sit were found
to be quite stable, although in some cases parts of the inhibitor left the enzyme. However, the
enzyme-inhibitor complex never split up completely. Furthermore, the distances between the cysteine
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moiety and the aromatic ring remained at distances above 4.5 Å, i.e., for these poses, an attack at the
substituted aromatic ring is unlikely.
MD simulations were also performed for the reverse, i.e., substrate-like binding mode given in
Figure 7. These simulations indicate a moderately stable complex. However, as shown in Figure 8a,
the distance between the cysteine moiety and the ester group increases along the simulation time.
Nevertheless, the ester may remain sufficiently long within the active site for an attack at the carbonyl
carbon followed by ester hydrolysis. To investigate possible differences between the ester and the
acid we performed an MD simulation starting from the pose given in Figure 7, but replaced the ester
group by the corresponding acid group. Figure 8b shows that in this case, the inhibitor leaves the
enzyme rapidly and the enzyme-inhibitor complex splits up completely. The behavior may result from
the repulsion between the negatively charged carboxylate and the negatively charged thiolate moiety
of Cys-25.
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located close the nucleophil c ysteine (distance 2.7 Å, score –18.03, Figure 9). The peptide backbone
has interactio s with Asp-161 and Gly-66, whi e the phenylalanin side chain occupies the hydrophobic
S2 pocket. The leucine side-chain and t e carboxylic cid group reside in the S3 pock t. One ni ro
group forms hydrogen bonds to Gl -19. To i vestigate the stability of the binding pose, we erform d
various MD sim lations, which ndicated a very st ble complex. The corres onding fluctuations in the
distances between the thiolate moi ty and the CH- and CNO2-groups of the aromatic ring are depict d
in Figure 10a,b, res ectively.
Our model computations indicate a stable pre-complex that is stabilized by a strong hydrogen
bond between the thiolate and the NH substituent of the aromatic ring. To investigate whether
this hydrogen bond is also important for the enzyme-inhibitor complex, we analyzed the distance
Cys-S. . . H-N between the sulfur center of Cys-25 and the proton of the NH substituent along our
MD simulations. The corresponding fluctuations are given in Figure 10c,d for two MD simulations,
which reflect the two different conformations that are adopted along these MD simulations. Both
conformations are depicted in Figure 11.
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hydrogen bond. While the distance Cys-S…H-N strongly differs between both conformations, the 
Figure 10. Charts (a,b) present the fluctuation of the distances between the sulfur center of Cys-25
and the carbon centers (CX) of the aromatic ring: (a) = distance S. . . CH; (b) = S. . . CNO2. (c,d) give
the fluctuation in the distance of the Cys-S. . . H-N hydrogen bond along MD 5 (c) and MD 6 (d).
All simulations start from the pose i i re 9.
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(MD) simulations starting from the pose depicted in Figure 9. The electrophilic aromatic ring is given
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of Cys-25 and the NH group (Cys-S. . . H-N) are given in black, while the distances to the CH group of
the ar matic ing (Cys-S. . . H-C) are given in red. For more information, see main text.
Within the pose epicted in i re , t - . . . H-N distance is around 4.5 Å, i.e., all D
simulations started from that distance. For some MDs this conformation was kept for the whole
simulation (Figure 10d, Fig re f ti it - . . . H-N = .4 Å). In other cases (Figure 10c,
Figure 11 confor ati it - . . . H-N = 2.5 Å), a presumably more stable conformation is adopted
in which the Cys-S. . . H-N distance decrease strongly and fluctuates around 2.2 Å, indicating a strong
hydrogen bond. While the distance ys-S. . . H-N strongly differs betw en both conformations, the
distances between the sulfur center of Cys-25 and the CH group of the substituted aromatic ring
(Cys-S. . . H-C) remains constant. The latter indicates a strong interaction between the catalytic dyad
Cys-25/His-162 and the electrophilic aromatic ring, which was also found for the model system (see
Section 2.6). It is worth noting that for poses of the ester 7 in which the electrophilic aromatic ring
was also in the vicinity of Cys-25 such a conformational change was not found. In the case of the
ester, all poses stayed in conformations with quite long Cys-S. . . H-N distances. This indicates that the
formation of the Cys-S. . . H-N bond is one reason for the strong inhibition potency of the acid, while
the corresponding ester does not show a comparably strong inhibition.
A complete nucleophilic substitution reaction would lead to an irreversible inhibition because the
eliminated group would diffuse away. Consequently, for a reversible inhibition the reaction must get
trapped in a minimum from which the elimination of the leaving group cannot happen. This minimum
cannot be a Meisenheimer complex as found for the model system with a single attacking thiolate
because in this complex, the bonds to the leaving groups are already elongated, i.e., an elimination
could occur. The pi-complex found for the model system consisting of a thiolate/imidazolium unit
instead of a single thiolate represents such a trap. It is more stable than the reactants and a further
approach of the thiolate towards the inhibitor, which is necessary for an SNAr reaction, cannot take
place because the underlying potential is repulsive. The question remains whether a similar situation
exists for the enzyme.
In many cases the enzyme environment strongly influences the reactivity of a given inhibitor [71–73].
To investigate the situation for the present question, possible reaction paths of the addition step of the
thiolate moiety to the aromatic ring including the influence of the enzyme environment were computed.
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For this instance, hybrid QM/MM computations were performed in which the most important part
is described quantum-mechanically (QM) while the influence of the rest is taken into account by
force field approaches (MM) using the ONIOM (own n-layered integrated molecular orbital and
molecular mechanics) approach implemented in GAUSSIAN16 [69]. Within these computations, the
QM part consisted of 35 atoms. It was described by SCS-MP2/6-31 + G* because theωB97XD values
underestimated the effects in the model computation. The influence of the rest of the enzyme (more
than 5200 atoms) was included into the MM part, which was described by the AMBER16 force field.
The electrostatic embedding was employed to include possible polarization effects. For the calculations,
some frames of the MD simulation performed for the complex of compound 8 and rhodesain were
selected, and a full geometry optimization was conducted using QM/MM. The resulting geometry
represents the starting point for a possible addition of the thiolate to the substituted aromatic ring as
the first step of the SNAr reaction. We computed the minimal energy path of the addition by decreasing
the distance between the thiolate and the two reachable carbon centers (C–H and C–NO2). For each
distance all other geometrical degrees of freedom were optimized. The results are depicted in Table 3.
Table 3. Shapes of various addition–reaction pathways of the Cys moiety to the substituted aromatic
rings. Relative energies [kcal/mol] are given with respect to the full geometry optimization. The full
optimization started from the indicated MD frame.
Starting Structure R(S-CNO2) R(S-CH) ∆E
MD 6 Frame 963
conformer with short
Cys-S. . . H-N distance
3.7 0.0
3.3 1.4
3.1 1.7
2.9 2.5
MD 6 Frame 1096
conformer with short
Cys-S. . . H-N distance
3.7 0.0
3.3 0.7
3.1 0.8
2.9 2.6
MD 6 Frame 542
conformer with short
Cys-S. . . H-N distance
4.9 0.0
4.5 1.2
4.1 3.4
3.9 0.4
3.5 5.3
Table 3 indeed indicates small minima in the reaction path. They appear at distances for R(S-CH) of
about 3.1–3.3 Å or for R(S-CNO2) of about 3.9 Å, i.e., in the range of the complex of the model ”thiolate
and imidazolium: full optimization” (Figure 6). They seem to be shallower than in the corresponding
model system. However, we expect that parts of the attractive forces between the catalytic dyad and
the substituted ring are already taken into account by the force field used for the MD simulations
or in the subsequent QM/MM geometry optimization, i.e., they already stabilize the minimum from
which the computation of the reaction paths started. Additionally, steric interactions may counteract.
Nevertheless, beside the indicated strong Cys-S. . . H-N hydrogen bond (see above), the underlying
interactions will contribute to the high inhibition potency of the acid 8 for rhodesain. The specific
nature and the interplay of the various interactions still have to be deciphered. As for the model
system, the computations for the enzyme environment also find a repulsive reaction path, so that a
Meisenheimer complex cannot be formed. As a consequence, a complete substitution reaction cannot
take place in the enzyme.
In summary, our QM/MM computations indicate that acid 8 and rhodesain form a very stable
pi-complex, which can explain the high inhibition potency of 8. Because the reaction path of the
formation of a Meisenheimer complex is repulsive, a SNAr reaction as found for the reaction of
2-phenylethanethiol with the ester 7 in the presence of a base in ethanol cannot take place in the
enzyme. This explains why acid 8 is a reversible inhibitor. The lower inhibitory potency of ester 7
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is a consequence of the non-covalent interactions between inhibitor and enzyme, which prevent the
formation of such a strong complex.
2.8. T. b. brucei Cell Survival Assay
Ester 7 and acid 8 were tested for their anti-trypanosomal activity against T. brucei brucei using the
ATPlite assay according to previously published procedures [74]. After 24 h, EC50 values of 0.0953
(±0.0402) µM for the ester 7 and 18.5 (±4.97) µM for the acid 8 were found (Figure 12). The differences
in anti-protease and anti-trypanosomal activity between the lipophilic ester 7 and the more hydrophilic
acid 8 might be due to different cell permeabilities of the compounds. With the acid 8 being the active
protease inhibitor and the more lipophilic benzyl ester 7 being the better anti-trypanosomal compound
that is converted to the active protease inhibitor 8 by the target enzyme itself, we presumably have
discovered a new prodrug concept for anti-trypanosomal compounds targeting the major trypanosomal
cysteine protease rhodesain. These results are in agreement with previous findings [75], which showed
that especially rhodesain inhibitors with benzyl ester moieties display high anti-trypanosomal activity.
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3. Discussion
The realm of potentially SNAr-reactive units as building blocks for protease inhibitors is still largely
unexplored and as stated in the introduction part, only very few steps have been undertaken in this
direction. The evaluation of (hetero)aromatic electrophiles as possible inhibitory fragments or warheads
for peptidic cysteine protease inhibitors is a first important step. Among the inhibitors presented
herein, which contain the dipeptide HN-l-Phe-l-Leu-OBn as the recognition unit for cathepsin L-like
proteases, the 2-fluoro-3-nitro-substituted benzoic acid amide 4 and the 2-fluoro-4,5-dinitro-substituted
aniline derivative 7 were discovered as very potent cathepsin L inhibitors. Amide 4 additionally
inhibits the trypanosomal cathepsin L-like protease rhodesain. The compounds were found to exhibit
a competitive and reversible mode of inhibition. As shown by NMR spectroscopy, mass spectrometry
and hydrolysis assays, the benzyl ester 7 was found to be hydrolyzed to the free acid 8 by rhodesain
to yield a highly potent reversible rhodesain inhibitor (Ki = 4.0 nM). Thus, with the benzyl ester 7,
we identified an unexpected prodrug that is converted into the active protease inhibitor by the target
enzyme itself. This is supported by the T. b. brucei cell survival assays, which revealed the benzyl ester
7 as a compound with significantly enhanced anti-trypanosomal activity. The serendipitous discovery
of the dual mode of action of compound 8 implies that other ester- or even amide-type inhibitors may
also react similarly. The ester 7 performed SNAr reactions with 2-phenylethanethiol in ethanol in the
presence of a base. Such a reaction is also expected for 8 because both possess the same substituted
aromatic ring. However, because 8 acts as a reversible inhibitor, such a reaction cannot be the inhibition
mechanism of rhodesain.
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To investigate possible inhibition mechanisms, QM computations for relevant model systems
were performed. Docking and MD simulation were conducted to detect and investigate possible
inhibitor-enzyme complexes of the compounds 7 and 8. Finally, QM/MM computations were carried
out to get some insights into possible reactions between 8 and rhodesain.
The model calculations show that a single attacking thiolate behaves completely different than a
dyad consisting of a thiolate and a positively charged imidazolium ring. The former is a model for the
reaction of phenylethanethiol in ethanol in the presence of a base, while the latter mimics the catalytic
dyad of the protease. For a single thiolate, the computations predict stable Meisenheimer complexes,
which is in line with the observed SNAr reactions. By contrast, for a thiolate/imidazolium dyad, a
stable pi-complex is found. The reaction potential of a further approach towards a Meisenheimer
complex is repulsive, i.e., the reaction cannot take place. Consequently, while an irreversible reaction
is predicted for a single thiolate, a reversible formation of a stable pi-complex is computed for the
thiolate/imidazolium dyad. Subsequent QM/MM computations simulating the reaction of 8 with
rhodesain indicate a similar situation. Hence, we expect that an SNAr reaction of acid 8 with rhodesain
does not take place because the reaction is trapped in a very stable pi-complex. The complex seems to
receive additional stability through a strong hydrogen bridge between the thiolate group of Cys-25
and the NH-substituent of the aromatic ring.
The conducted docking and MD simulations reveal several stable complexes between ester 7
and rhodesain, in which the substituted aromatic ring sits in the active site, i.e., in close vicinity to
the reactive dyad. Nevertheless, reactions are not expected because MD simulations show that the
distances are still too large. Additionally, no indication for the formation of a stable pi-complex or
the thiolate-NH bridge is seen. Hence, we expect that these complexes are less stable, which nicely
explains the lower inhibitory potency of ester 7 compared to acid 8. Docking also predicts a reverse,
substrate-like binding pose, which is ideal for the hydrolysis of the ester through rhodesain. MD
simulations find this pose to be reasonably stable. For the acid 8 in rhodesain, docking and MD find
very stable complexes in which the substituted aromatic ring and the catalytic Cys-25/His-162 dyad are
sufficiently close. However, as described above, the reaction path towards the Meisenheimer complex
only exhibits shallow minima for large distances (R(S-CH) or R(S-CNO2) ≈ 3.1 – 4.0 Å) while it is
repulsive for a further approach. This finding is in line with the reversible inhibition of rhodesain by
acid 8.
In summary, with the benzyl ester 7, we present an efficient prodrug that has a strong
anti-trypanosomal effect and inhibits the trypanosomal protease rhodesain in vitro via the hydrolysis
and subsequent reversible binding of the hydrolysis product 8 via a pi-complex. In future studies, we
will address the question if esters other than benzyl can also be used as prodrugs.
4. Materials and Methods
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